spironolactone has been researched along with 2019 Novel Coronavirus Disease in 14 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All patients had a confirmed 2019 novel coronavirus infection (COVID 19) based on a positive polymerase chain reaction (PCR) for SARS-CoV-2 virus RNA and/or a typical pattern of viral pneumonia on multispiral computed tomography." | 2.94 | [Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)]. ( Agapov, MA; Akopyan, ZA; Asratyan, DA; Begrambekova, YL; Bulanova, MM; Dyachuk, LI; Fuks, AA; Kamalov, АА; Mareev, VY; Mareev, YV; Matskeplishvili, ST; Mershina, ЕА; Orlova, YA; Pakhomov, PV; Pavlikova, EP; Plisyk, AG; Potapenko, AV; Samokhodskaya, LM; Seredenina, EM; Sinitsyn, VE, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 14 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orlova, YA | 3 |
| Begrambekova, YL | 3 |
| Plisuk, AG | 1 |
| Kumar, N | 1 |
| Zuo, Y | 1 |
| Yalavarthi, S | 1 |
| Hunker, KL | 1 |
| Knight, JS | 1 |
| Kanthi, Y | 1 |
| Obi, AT | 1 |
| Ganesh, SK | 1 |
| Edwards, C | 3 |
| Klekot, O | 1 |
| Halugan, L | 1 |
| Korchev, Y | 1 |
| Bakhtiari, M | 1 |
| Asadipooya, K | 1 |
| Fels, B | 1 |
| Acharya, S | 1 |
| Vahldieck, C | 1 |
| Graf, T | 1 |
| Käding, N | 1 |
| Rupp, J | 1 |
| Kusche-Vihrog, K | 1 |
| Wadhwa, B | 1 |
| Malhotra, V | 1 |
| Kerai, S | 1 |
| Husain, F | 1 |
| Pandey, NB | 1 |
| Saxena, KN | 1 |
| Singh, V | 1 |
| Quinn, TM | 1 |
| Li, F | 1 |
| Gaughan, E | 1 |
| Shankar-Hari, M | 1 |
| Mills, B | 1 |
| Antonelli, J | 1 |
| Bruce, A | 1 |
| Finlayson, K | 1 |
| Moore, A | 1 |
| Dhaliwal, K | 1 |
| Cousins, HC | 1 |
| Kline, AS | 1 |
| Wang, C | 1 |
| Qu, Y | 1 |
| Zengel, J | 1 |
| Carette, J | 1 |
| Wang, M | 1 |
| Altman, RB | 1 |
| Luo, Y | 1 |
| Cong, L | 1 |
| Cadegiani, FA | 3 |
| Liaudet, L | 1 |
| Szabo, C | 1 |
| Goren, A | 2 |
| Wambier, CG | 2 |
| Herrera, S | 1 |
| McCoy, J | 1 |
| Vaño-Galván, S | 1 |
| Gioia, F | 1 |
| Comeche, B | 1 |
| Ron, R | 1 |
| Serrano-Villar, S | 1 |
| Ramos, PM | 1 |
| Kovacevic, M | 1 |
| Tosti, A | 1 |
| Shapiro, J | 1 |
| Sinclair, R | 1 |
| Mareev, VY | 2 |
| Pavlikova, EP | 2 |
| Matskeplishvili, ST | 2 |
| Akopyan, ZA | 2 |
| Plisyk, AG | 2 |
| Seredenina, EM | 2 |
| Asratyan, DA | 2 |
| Potapenko, AV | 2 |
| Malakhov, PS | 1 |
| Samokhodskaya, LM | 2 |
| Mershina, EA | 1 |
| Sinitsyn, VE | 2 |
| Bulanova, MM | 2 |
| Fuks, AA | 2 |
| Mareev, YV | 2 |
| Kamalov, AA | 1 |
| Agapov, MA | 1 |
| Dyachuk, LI | 1 |
| Mershina, ЕА | 1 |
| Pakhomov, PV | 1 |
| Kamalov, АА | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for spironolactone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage.
Topics: COVID-19; COVID-19 Drug Treatment; Cytokines; Endothelial Cells; Glycocalyx; Humans; Interleukin-6; | 2022 |
2 trials available for spironolactone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi.
Topics: Aldosterone; Angiotensin II; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Randomized Co | 2023 |
[Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)].
Topics: Bromhexine; Coronavirus Infections; COVID-19; Hospitalization; Humans; Prospective Studies; SARS-CoV | 2020 |
11 other studies available for spironolactone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
[Expert opinion. Spironolactone: a new twist on an old story].
Topics: COVID-19; Expert Testimony; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; SARS-CoV-2 | 2021 |
SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism.
Topics: Angiotensin Receptor Antagonists; Cell Adhesion Molecules; Cells, Cultured; COVID-19; Dihydrotestost | 2021 |
Follow Your Nose: A Key Clue to Understanding and Treating COVID-19.
Topics: Adenosine Triphosphate; Adult; Aged; Angiopoietin-2; Angiotensin-Converting Enzyme 2; Animals; Anosm | 2021 |
Metainflammation in COVID-19.
Topics: Aged; Angiotensin-Converting Enzyme 2; COVID-19; Dipeptidyl Peptidase 4; Eplerenone; Female; Humans; | 2022 |
Integrative analysis of functional genomic screening and clinical data identifies a protective role for spironolactone in severe COVID-19.
Topics: COVID-19; Genomics; Humans; Retrospective Studies; SARS-CoV-2; Spironolactone | 2023 |
Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Coronavi | 2020 |
Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.
Topics: Coronavirus Infections; COVID-19; Humans; Mineralocorticoid Receptor Antagonists; Pandemics; Pneumon | 2020 |
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Topics: Androgen Antagonists; Androgens; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhi | 2020 |
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; COVID-19; Dutasteride; Finasteride; Humans; Intensive | 2021 |
[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)"].
Topics: Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hospitalizat | 2020 |
New Horizons: Does Mineralocorticoid Receptor Activation by Cortisol Cause ATP Release and COVID-19 Complications?
Topics: Adenosine Triphosphate; Angiotensin-Converting Enzyme 2; Blood Coagulation Disorders; COVID-19; COVI | 2021 |